Analysis of the layout of anti cancer drugs in China: ten billion market is surging

Among many antitumor drugs, tinii plays a very important role. Statistics show that China’s sales of tinibacin drugs in 2018 will exceed 10 billion yuan, in front of such a big cake, the major pharmaceutical companies have layout, the market is surging. Now let’s take a look at these drugs.


Table 1 Domestic listed drugs

Table 1 lists 13 tinib drugs listed so far in China, including Novartis’s Imatinib, Nilotinib, AstraZeneca’s Gefitinib, Osimertinib, OSI Pharmaceuticals’s Erlotinib and Pfizer’s Sunitinib, Axitinib, Crizotinib, Dasatinib, Lapatinib, Lcotinib, Beida, Zhejiang, Apatinib, Bremssch Afatinib, under the banner of Graham. From the table, we can see that the approved tinibacin drugs mainly for lung cancer, leukemia and other high incidence of cancer types in China; and from the perspective of development enterprises, tinibacin drugs were approved into China’s largest Pfizer, followed by Novartis, AstraZeneca and other pharmaceutical giants.


Post time: Aug-10-2018
WhatsApp Online Chat !